Contributing Writer
https://x.com/ScottNover
https://www.linkedin.com/in/scottnover/
Scott Nover
Contributing Writer
Scott Nover is the lead writer for GZERO AI. He's a contributing writer for Slate and was previously a staff writer at Quartz and Adweek. His writing has appeared in The Atlantic, Fast Company, Vox.com, and The Washington Post, among other outlets. He currently lives near Washington, DC, with his wife and pup.
Apr 01, 2025
In 2024, Demis Hassabiswon a Nobel Prize in chemistry for his work in predicting protein structures through his company, Isomorphic Labs. The lab, which broke off from Google's DeepMind in 2021, raised $600 million from investors in a new funding round led by Thrive Capital on Monday. The company did not disclose a valuation.
Isomorphic uses artificial intelligence to discover new drugs through its AlphaFold technology, which was at the center of Hassabis’s Nobel win last year. Ultimately, Hassabis wants to do something that’s not exactly simple: He’s vowed to “solve all disease with the help of AI.”
Isomorphic is already working with big pharmaceutical companies such as Eli Lilly and Novartis, inking deals with the two drugmakers last year worth $3 billion. It plans to use the new money to improve its AI tools and to move its drugs toward clinical testing.
